Everything below concerns preclinical model. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-22. Numbers and descriptions here follow the published literature rather than marketing material.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Assessed by visual inspection under ordinary laboratory lighting |
| Molecular mass | Approximately 1419 Da | Monoisotopic mass for the fifteen-residue sequence |
| Solubility class | Freely soluble in water | Stock solutions commonly prepared in water or aqueous buffer |
| Typical storage temperature | -20 °C or below, desiccated | Lyophilized powder; repeated freeze-thaw cycles are usually avoided |
| Common analytical method | Reversed-phase HPLC with UV detection | Frequently paired with mass spectrometry to confirm identity |
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
There are two recorded instances of the parasitic cookiecutter shark targeting white sharks off Guadalupe, though the scarcity of such records suggests white sharks are not a primary food source for them. As many as 116 parasite species infest white sharks, including copepod crustaceans—such as Nesippus orientalis, Nemesis lamna, and Dinemoura latifolia—which attach to the skin, fins, mouth, and gills. The white shark is the primary host of two species of tapeworms from the genus Clistobothrium; Clistobothrium carcharodoni and Clistobothrium tumidum. The former is believed to be transmitted to white sharks through the consumption of infected cetacean prey, while the transmission source of C. tumidum is unknown. The intensity of C. carcharodoni infestations can be remarkably high; in one documented case, as many as 2,533 specimens were recovered from the spiral valve of a single individual.
Two-stroke chainsaws require about 2–5% of oil in the fuel to lubricate the engine, while the motor in electrical chain-saws is normally lubricated for life. Most modern gasoline-operated saws today require a fuel mix of 2% (1:50). Gasoline that contains ethanol can result in problems for the equipment because ethanol dissolves plastic, rubber, and other material. This leads to problems, especially on older equipment. A workaround for this problem is to run fresh fuel only and run the saw dry at the end of the work. Separate chain oil or bar oil is used for the lubrication of the bar and chain on all types of chainsaws. The chain oil is depleted because it tends to be thrown off by chain centrifugal force. On two-stroke chainsaws, the chain oil reservoir is usually filled up at the same time as refueling. The reservoir is normally large enough to provide sufficient chain oil between refueling. Lack of chain oil, or using an oil of incorrect viscosity, is a common source of damage to chainsaws, and tends to lead to rapid wear of the bar, or the chain seizing or coming off the bar. In addition to being quite thick, chain oil is particularly sticky (due to "tackifier" additives) to reduce the amount thrown off the chain. Although motor oil is a common emergency substitute, it is lost even faster, leaving the chain less lubricated. Oil is pumped from a small pump to a hole in the bar. From there, the lower ends of each chain drive link take a portion of the oil into the gauge towards the bar nose. The pump outlet and bar hole must be aligned.
=== Bacteriophage Morphology === In 1956, Kaesberg and his colleagues studied staphylococcus bacteriophages via electron microscopy and found that freeze-dried particles and air-dried particles had significant morphological differences, specifically in size and shape. They were then able to classify the phages into two serological categories: large with flattened heads and long tails and smaller with long tails and circular heads. They noted that phages within the same class had structural similarities, and phages from different classes differed in structure.
== History == Leveraging advanced computational bioinformatics, brilacidin and other defensin mimetics were first developed by University of Pennsylvania-based researchers. Their efforts were consolidated, and officially incorporated, in 2002, under the company name PolyMedix. PolyMedix conducted pre-clinical and clinical research with brilacidin through a completed Phase 2a human clinical trial with positive results. After discontinuing a clinical trial for an unrelated compound PolyMedix filed for Chapter 7 bankruptcy protection on 1 April 2013. Cellceutix acquired the PolyMedix assets and intellectual property, including the licenses and patents for brilacidin and the rest of the HDP-mimetic pipeline, from bankruptcy court which on 4 September 2013, approved Cellceutix's stalking horse bid. On 7 June 2017, Cellceutix Announced a Company Name Change to Innovation Pharmaceuticals Inc. On 9 June 2017, the stock ticker name was effectively changed to "IPIX".
L-proline amide hydrolase (EC 3.5.1.101, S-stereoselective piperazine-2-tert-butylcarboxamide hydrolase, LaaA, L-amino acid amidase) is an enzyme with systematic name (S)-piperidine-2-carboxamide amidohydrolase. It catalyses several related hydrolysis reactions. For example, prolinamide is converted to proline:
Sources: en.wikipedia.org
In it, she stated she administered that insulin to patients that she believed were suffering so that they could pass away "gently." She also stated that she had great stress and chaos in both her personal and professional life and that her actions gave her a sense of control. On May 11, 2021, Mays was sentenced to seven consecutive life sentences, plus 20 years, during a three-hour-long hearing at the United States District Court for the Northern District of West Virginia in Clarksburg by U.S. District Judge Thomas Kleeh. Mays is ineligible for parole. During the sentencing, Mays, in tears, gave a brief statement: "There’s no words I can say that can offer the families any comfort. I can only say I’m sorry for the pain I caused them and my family." In addition to her sentence, Mays was ordered to pay $172,624.96 to the victims' families, the VA Hospital, Medicare, and insurance companies. The judge, speaking directly to Mays, stated, "Several times your counsels made the point that you shouldn't be considered a monster. Respectfully, I disagree with that. You are the worst kind. You're the monster that no one sees coming." In July 2021, Mays was transferred to the low-security Federal Correctional Institution, Aliceville in Alabama. U.S. District Judge Thomas Kleeh had recommended that Mays be placed at Federal Medical Center, Carswell, in Fort Worth, Texas, so that she could receive mental health treatment there; the BOP ultimately assigned her to Aliceville. Since Mays' guilty pleas, the federal government has settled civil lawsuits with the families of 10 victims.
24395Am + 188O → 261103Lr* → 256103Lr + 5 10n Further experiments in 1969 at Dubna, and in 1970 at Berkeley, demonstrated an actinide chemistry for the new element; so by 1970 it was known that element 103 is the last actinide. In 1970, the Dubna group reported the synthesis of 255Lr with half-life 20 s and alpha decay energy 8.38 MeV. However, it was not until 1971, when the nuclear physics team at University of California at Berkeley successfully did a whole series of experiments aimed at measuring the nuclear decay properties of the lawrencium isotopes with mass numbers 255 to 260, that all previous results from Berkeley and Dubna were confirmed, apart from the Berkeley's group initial erroneous assignment of their first produced isotope to 257Lr instead of the probably correct 258Lr. All final doubts were dispelled in 1976 and 1977 when the energies of X-rays emitted from 258Lr were measured.
(S)-PhCH2CH(CH3)NH2 + (S)-HOOCCH(NH2)CH2CH2CH2CH2NH2 → (S,S)-PhCH2CH(CH3)NHC(O)CH(NH2)CH2CH2CH2CH2NH2 + H2O Amine functional groups are vulnerable to oxidation in air and so pharmaceuticals containing them are usually formulated as salts where this moiety has been protonated. This increases stability, water solubility, and, by converting a molecular compound to an ionic compound, increases the melting point and thereby ensures a solid product. In the case of lisdexamphetamine, this is achieved by reacting with two equivalents of methanesulfonic acid to produce the dimesylate salt, a water-soluble (792 mg mL−1) powder with a white to off-white color.
=== Controversy === Use of this class of drugs has a history of criticism in residential care. As the drugs used can make patients calmer and more compliant, critics claim that the drugs can be overused. Outside doctors can feel under pressure from care home staff. In an official review commissioned by UK government ministers it was reported that the needless use of antipsychotic medication in dementia care was widespread and was linked to 1800 deaths per year. In the US, the government has initiated legal action against the pharmaceutical company Johnson & Johnson for allegedly paying kickbacks to Omnicare to promote its antipsychotic risperidone (Risperdal) in nursing homes. There has also been controversy about the role of pharmaceutical companies in marketing and promoting antipsychotics, including allegations of downplaying or covering up adverse effects, expanding the number of conditions or illegally promoting off-label usage; influencing drug trials (or their publication) to try to show that the expensive and profitable newer atypicals were superior to the older cheaper typicals that were out of patent. Following charges of illegal marketing, settlements by two large pharmaceutical companies in the US set records for the largest criminal fines ever imposed on corporations. One case involved Eli Lilly and Company's antipsychotic Zyprexa, and the other involved Bextra. In the Bextra case, the government also charged Pfizer with illegally marketing another antipsychotic, Geodon.
Sources: en.wikipedia.org
== External links == "Discrimination des femmes à l'embauche" [Discrimination against women in hiring] (in French). Archived from the original on March 28, 2007. "Hommes et femmes" [Men and women]. Observatoire des Inégalités (in French). Archived from the original on February 19, 2007. "Lutte contre les discriminations et promotion de l'égalité" [Fighting discrimination and promoting equality]. Defenseurs des droits (in French). Archived from the original on June 13, 2017. "La discrimination des femmes : un sujet d'actualité" [Discrimination against women: a topical issue]. CentrOjeunes (in French). December 6, 2012. Archived from the original on August 8, 2016. "Discrimination des femmes à l'embauche" [Discrimination against women in hiring] (in French). Archived from the original on March 28, 2007. "Haut conseil à l'égalité des droits" [High Council for Equal Rights]. Haut Conseil a L'égalité entre les femmes et les hommes (in French). Archived from the original on May 22, 2013. "Secrétariat d'état chargé de l'égalité entre femmes et hommes et de la lutte contre les discriminations" [State Secretariat for Gender Equality and Anti-Discrimination]. Haut Conseil a L'égalité entre les femmes et les hommes (in French). Archived from the original on January 7, 2013. "Maison de la justice et du droit" [House of Justice and Law] (in French). Archived from the original on April 12, 2013. "Association européenne contre les Violences faites aux Femmes au Travail" [European Association Against Violence Against Women at Work] (in French).
== People with the name == Link (singer) (Lincoln Browder, born 1964), American R&B singer Link (surname) Charles Lincoln "Link" Neal III of Rhett & Link (born 1978), American comedian and YouTuber Link Wray (1929–2005), American rock-and-roll guitarist
=== Pharmacokinetics === Following oral administration, dextromethorphan is rapidly absorbed from the gastrointestinal tract, where it enters the bloodstream and crosses the blood–brain barrier. At therapeutic doses, dextromethorphan acts centrally (meaning that it acts on the brain) as opposed to locally (on the respiratory tract). It elevates the threshold for coughing, without inhibiting ciliary activity. Dextromethorphan is rapidly absorbed from the gastrointestinal tract and converted into the active metabolite dextrorphan in the liver by the cytochrome P450 enzyme CYP2D6. The average dose necessary for effective antitussive therapy is between 10 and 45 mg, depending on the individual. The International Society for the Study of Cough recommends "an adequate first dose of medication is 60 mg in the adult and repeat dosing should be infrequent rather than qds recommended." Dextromethorphan has an elimination half-life of approximately four hours in individuals with an extensive metabolizer phenotype; this is increased to approximately 13 hours when dextromethorphan is given in combination with quinidine. The duration of action after oral administration is about three to eight hours for dextromethorphan hydrobromide, and 10 to 12 hours for dextromethorphan polistirex. Around one in ten of the Caucasian population has little or no CYP2D6 enzyme activity, leading to long-lived high drug levels.
Sources: en.wikipedia.org
It is a synthetic peptide built from fifteen amino acids, with a mass of roughly 1419 daltons. The sequence is reported to match a fragment of a protein present in human gastric juice. It is not a naturally circulating hormone.
It is normally supplied as a lyophilized powder in a sealed vial. The powder dissolves readily in water, and stock solutions are typically prepared shortly before use. Cold storage is standard laboratory practice.
The letters are generally read as shorthand for body protection compound. That label comes from the original research context rather than from formal nomenclature. No standardized nonproprietary name exists for the peptide.
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.